Cargando…

PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis

The encapsulation of Glucocorticoids (GCs) into long-circulating liposomes (LCLs) is a proven strategy to reduce the side effects of glucocorticoids and improve the treatment of inflammatory diseases, such as rheumatoid arthritis (RA). With the aim of supporting the development of GC-loaded LCLs, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gawne, Peter J., Clarke, Fiona, Turjeman, Keren, Cope, Andrew P., Long, Nicholas J., Barenholz, Yechezkel, Terry, Samantha Y. A., de Rosales, Rafael T. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086351/
https://www.ncbi.nlm.nih.gov/pubmed/32226525
http://dx.doi.org/10.7150/thno.40403
_version_ 1783509109288468480
author Gawne, Peter J.
Clarke, Fiona
Turjeman, Keren
Cope, Andrew P.
Long, Nicholas J.
Barenholz, Yechezkel
Terry, Samantha Y. A.
de Rosales, Rafael T. M.
author_facet Gawne, Peter J.
Clarke, Fiona
Turjeman, Keren
Cope, Andrew P.
Long, Nicholas J.
Barenholz, Yechezkel
Terry, Samantha Y. A.
de Rosales, Rafael T. M.
author_sort Gawne, Peter J.
collection PubMed
description The encapsulation of Glucocorticoids (GCs) into long-circulating liposomes (LCLs) is a proven strategy to reduce the side effects of glucocorticoids and improve the treatment of inflammatory diseases, such as rheumatoid arthritis (RA). With the aim of supporting the development of GC-loaded LCLs, and potentially predict patient response to therapy clinically, we evaluated a direct PET imaging radiolabelling approach for preformed GC-LCLs in an animal model of human inflammatory arthritis. Methods: A preformed PEGylated liposomal methylprednisolone hemisuccinate (NSSL-MPS) nanomedicine was radiolabelled using [(89)Zr]Zr(oxinate)(4) ((89)Zr-oxine), characterised and tracked in vivo using PET imaging in a K/BxN serum-transfer arthritis (STA) mouse model of inflammatory arthritis and non-inflamed controls. Histology and joint size measurements were used to confirm inflammation. The biodistribution of (89)Zr-NSSL-MPS was compared to that of free (89)Zr in the same model. A therapeutic study using NSSL-MPS using the same time points as the PET/CT imaging was carried out. Results: The radiolabelling efficiency of NSSL-MPS with [(89)Zr]Zr(oxinate)(4) was 69 ± 8 %. PET/CT imaging of (89)Zr-NSSL-MPS showed high uptake (3.6 ± 1.5 % ID; 17.4 ± 9.3 % ID/mL) at inflamed joints, with low activity present in non-inflamed joints (0.5 ± 0.1 % ID; 2.7 ± 1.1 % ID/mL). Importantly, a clear correlation between joint swelling and high (89)Zr-NSSL-MPS uptake was observed, which was not observed with free (89)Zr. STA mice receiving a therapeutic dose of NSSL-MPS showed a reduction in inflammation at the time points used for the PET/CT imaging compared with the control group. Conclusions: PET imaging was used for the first time to track a liposomal glucocorticoid, showing high uptake at visible and occult inflamed sites and a good correlation with the degree of inflammation. A subsequent therapeutic response matching imaging time points in the same model demonstrated the potential of this radiolabeling method as a theranostic tool for the prediction of therapeutic response - with NSSL-MPS and similar nanomedicines - in the treatment of inflammatory diseases
format Online
Article
Text
id pubmed-7086351
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-70863512020-03-27 PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis Gawne, Peter J. Clarke, Fiona Turjeman, Keren Cope, Andrew P. Long, Nicholas J. Barenholz, Yechezkel Terry, Samantha Y. A. de Rosales, Rafael T. M. Theranostics Research Paper The encapsulation of Glucocorticoids (GCs) into long-circulating liposomes (LCLs) is a proven strategy to reduce the side effects of glucocorticoids and improve the treatment of inflammatory diseases, such as rheumatoid arthritis (RA). With the aim of supporting the development of GC-loaded LCLs, and potentially predict patient response to therapy clinically, we evaluated a direct PET imaging radiolabelling approach for preformed GC-LCLs in an animal model of human inflammatory arthritis. Methods: A preformed PEGylated liposomal methylprednisolone hemisuccinate (NSSL-MPS) nanomedicine was radiolabelled using [(89)Zr]Zr(oxinate)(4) ((89)Zr-oxine), characterised and tracked in vivo using PET imaging in a K/BxN serum-transfer arthritis (STA) mouse model of inflammatory arthritis and non-inflamed controls. Histology and joint size measurements were used to confirm inflammation. The biodistribution of (89)Zr-NSSL-MPS was compared to that of free (89)Zr in the same model. A therapeutic study using NSSL-MPS using the same time points as the PET/CT imaging was carried out. Results: The radiolabelling efficiency of NSSL-MPS with [(89)Zr]Zr(oxinate)(4) was 69 ± 8 %. PET/CT imaging of (89)Zr-NSSL-MPS showed high uptake (3.6 ± 1.5 % ID; 17.4 ± 9.3 % ID/mL) at inflamed joints, with low activity present in non-inflamed joints (0.5 ± 0.1 % ID; 2.7 ± 1.1 % ID/mL). Importantly, a clear correlation between joint swelling and high (89)Zr-NSSL-MPS uptake was observed, which was not observed with free (89)Zr. STA mice receiving a therapeutic dose of NSSL-MPS showed a reduction in inflammation at the time points used for the PET/CT imaging compared with the control group. Conclusions: PET imaging was used for the first time to track a liposomal glucocorticoid, showing high uptake at visible and occult inflamed sites and a good correlation with the degree of inflammation. A subsequent therapeutic response matching imaging time points in the same model demonstrated the potential of this radiolabeling method as a theranostic tool for the prediction of therapeutic response - with NSSL-MPS and similar nanomedicines - in the treatment of inflammatory diseases Ivyspring International Publisher 2020-02-26 /pmc/articles/PMC7086351/ /pubmed/32226525 http://dx.doi.org/10.7150/thno.40403 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Gawne, Peter J.
Clarke, Fiona
Turjeman, Keren
Cope, Andrew P.
Long, Nicholas J.
Barenholz, Yechezkel
Terry, Samantha Y. A.
de Rosales, Rafael T. M.
PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
title PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
title_full PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
title_fullStr PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
title_full_unstemmed PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
title_short PET Imaging of Liposomal Glucocorticoids using (89)Zr-oxine: Theranostic Applications in Inflammatory Arthritis
title_sort pet imaging of liposomal glucocorticoids using (89)zr-oxine: theranostic applications in inflammatory arthritis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086351/
https://www.ncbi.nlm.nih.gov/pubmed/32226525
http://dx.doi.org/10.7150/thno.40403
work_keys_str_mv AT gawnepeterj petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT clarkefiona petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT turjemankeren petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT copeandrewp petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT longnicholasj petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT barenholzyechezkel petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT terrysamanthaya petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis
AT derosalesrafaeltm petimagingofliposomalglucocorticoidsusing89zroxinetheranosticapplicationsininflammatoryarthritis